The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma
NCT07514533
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Cholangiocarcinoma
Interventions
DRUG:
Vibecototamab（iv）+Putilimab（iv）
Sponsor
Sir Run Run Shaw Hospital